Overview

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Status:
Recruiting

Trial end date:
2029-04-23

Target enrollment:

Participant gender:

Summary

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Daiichi Sankyo

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Durvalumab
Gemcitabine
Paclitaxel
Pembrolizumab